Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 484,175
  • Shares Outstanding, K 76,610
  • Annual Sales, $ 17,400 K
  • Annual Income, $ -155,640 K
  • 60-Month Beta 1.73
  • Price/Sales 30.11
  • Price/Cash Flow N/A
  • Price/Book 6.00
Trade OCUL with:

Options Overview Details

View History
  • Implied Volatility 104.22%
  • Historical Volatility 63.23%
  • IV Percentile 51%
  • IV Rank 29.51%
  • IV High 184.38% on 01/26/21
  • IV Low 70.66% on 07/22/21
  • Put/Call Vol Ratio 0.11
  • Today's Volume 185
  • Volume Avg (30-Day) 804
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 8,136
  • Open Int (30-Day) 14,546

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.23
  • Number of Estimates 4
  • High Estimate -0.21
  • Low Estimate -0.26
  • Prior Year -0.23
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.31 +0.16%
on 12/01/21
7.86 -19.59%
on 11/09/21
-0.76 (-10.73%)
since 11/01/21
3-Month
6.31 +0.16%
on 12/01/21
12.50 -49.44%
on 10/13/21
-4.47 (-41.43%)
since 09/01/21
52-Week
6.31 +0.16%
on 12/01/21
24.30 -73.99%
on 12/16/20
-11.64 (-64.81%)
since 12/01/20

Most Recent Stories

More News
Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences

Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 6.32 (-7.60%)
Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 6.32 (-7.60%)
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 11.54% and 0.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

OCUL : 6.32 (-7.60%)
Ocular Therapeutix: Q3 Earnings Snapshot

BEDFORD, Mass. (AP) _ Ocular Therapeutix Inc. (OCUL) on Monday reported third-quarter earnings of $2.7 million.

OCUL : 6.32 (-7.60%)
Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 6.32 (-7.60%)
Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced...

OCUL : 6.32 (-7.60%)
Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced...

OCUL : 6.32 (-7.60%)
Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results

Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 6.32 (-7.60%)
Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced...

OCUL : 6.32 (-7.60%)
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint

Ocular Therapeutix, Inc. (Nasdaq:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 6.32 (-7.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

3rd Resistance Point 7.38
2nd Resistance Point 7.17
1st Resistance Point 6.74
Last Price 6.32
1st Support Level 6.10
2nd Support Level 5.89
3rd Support Level 5.46

See More

52-Week High 24.30
Fibonacci 61.8% 17.43
Fibonacci 50% 15.30
Fibonacci 38.2% 13.18
Last Price 6.32
52-Week Low 6.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar